EDIT vs IPSC
EDIT: A gene editing pioneer leveraging CRISPR technology to develop in vivo, one-time therapies for serious genetic diseases. IPSC: Century Therapeutics is pioneering scalable, off-the-shelf allogeneic cell therapies using an iPSC-derived platform to treat autoimmune diseases and cancer.
Side-by-side fundamentals
| Metric | EDIT | IPSC | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $2.58 | $1.64 | |
| Market cap | $396M | $297M | |
| Net margin FY2025, SEC XBRL | -395.0% | -8.8% | IPSC higher |
| Operating margin FY2025, SEC XBRL | -394.9% | -15.8% | IPSC higher |
| ROE FY2025, SEC XBRL | -586.6% | -6.0% | IPSC higher |
| ROA FY2025, SEC XBRL | -85.8% | -4.3% | IPSC higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.53 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +25.4% | +1556.8% | IPSC higher |
| Revenue CAGR (3y) SEC XBRL | +27.1% | +175.9% | IPSC higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.24 | 1.52 | |
| 1-year return as of 2026-10-20 close | -37.7% | +187.2% | IPSC higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.